Literature DB >> 10516349

Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: A double-blind randomized trial.

S Thomas1, F P Fischer, T Mettang, C Pauli-Magnus, J Weber, U Kuhlmann.   

Abstract

Excess morbidity and mortality among long-term hemodialysis patients because of infectious complications is partly caused by an impairment of cellular immune defense. We hypothesized this impairment is related to an abnormal carnitine metabolism also present in these patients. In a double-blind, randomized, placebo-controlled trial, we investigated the effect of L-carnitine on phagocytic function and viability of blood leukocytes in 17 patients undergoing maintenance hemodialysis. After an observation period of 1 month, the patients received either 10 mg/kg of L-carnitine or placebo intravenously at the end of each hemodialysis session over a period of 4 months. Leukocyte oxidative metabolism was measured by means of luminol-enhanced chemiluminescence and superoxide generation after stimulation with Staphylococcus aureus or phorbol myristate acetate. Killing capacity and phagocytosis of radiolabeled staphylococci were determined. A lactate dehydrogenase (LDH) release test was applied to assess cell viability. We were unable to show an effect of L-carnitine on phagocytic function and viability in vivo. Several clinical parameters were observed during the trial. No statistically significant differences concerning dialysis-related morbidity, anemia, or reduction of blood urea nitrogen and creatinine levels were detected. Additionally, we tested the effect of L-carnitine on phagocytic function after in vitro incubation of blood leukocytes, which also showed no changes. LDH release was decreased, indicating an improved viability of these cells. The latter results were found after in vitro incubation of cells, but could not be confirmed in vivo. In summary, we could not show beneficial effects of L-carnitine administration in hemodialysis patients for the dosage and duration of treatment stated, either on phagocytic function and viability or on the clinical and biochemical parameters observed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516349     DOI: 10.1016/S0272-6386(99)70393-8

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  5 in total

Review 1.  Effect of L-carnitine therapy on patients in maintenance hemodialysis: a systematic review and meta-analysis.

Authors:  Shi-Kun Yang; Li Xiao; Pan-Ai Song; Xiaoxuan Xu; Fu-You Liu; Lin Sun
Journal:  J Nephrol       Date:  2013-12-17       Impact factor: 3.902

2.  Effect of L-carnitine supplementation on renal anemia in patients on hemodialysis: a meta-analysis.

Authors:  Yan Zhu; Chao Xue; Jihong Ou; Zhijuan Xie; Jin Deng
Journal:  Int Urol Nephrol       Date:  2021-03-13       Impact factor: 2.370

3.  Interventions for itch in people with advanced chronic kidney disease.

Authors:  Daniel Hercz; Simon H Jiang; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2020-12-07

Review 4.  Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials.

Authors:  Giovanni Pagano; Annarita Aiello Talamanca; Giuseppe Castello; Mario D Cordero; Marco d'Ischia; Maria Nicola Gadaleta; Federico V Pallardó; Sandra Petrović; Luca Tiano; Adriana Zatterale
Journal:  Int J Mol Sci       Date:  2014-11-05       Impact factor: 5.923

Review 5.  Significance of Levocarnitine Treatment in Dialysis Patients.

Authors:  Hiroyuki Takashima; Takashi Maruyama; Masanori Abe
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.